Last reviewed · How we verify
Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans
The symptoms and severity of arterial disease is secondary to perfusion deficit. The specific alteration of the mitochondrial function of ischemic skeletal muscle plays an important role, and therapeutic enhancing mitochondrial function are associated with a clinical improvement with increase in the walking distance of the patient. In severe ischemia, reperfusion required is accompanied by a deleterious episode through a worsening of endothelial dysfunction (impaired pathway of nitric oxide (NO)), majorant alteration of cellular energy and the hormonal and inflammatory responses. This is reperfusion syndrome, which can lead to grave consequences. Our goal is to limit mitochondrial and endothelial dysfunction (increased by the reperfusion) by stimulating the NO pathway by in situ addition of its precursor, L-arginine. Our working hypothesis is that this cellular improvement will be accompanied by an increase in systolic pressure index and an improvement in the walking distance. Method: This is a trial with direct individual benefit, comparative, randomized, prospective, single-center, double-blind, versus placebo.
Details
| Lead sponsor | University Hospital, Strasbourg, France |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | 2005-11 |
| Completion | 2013-11 |
Conditions
- Skeletal Muscle Ischemia
- Severe Lower Limb Ischemia
- Mitochondrial Dysfunction
Interventions
- L-arginine (L-arginine Veyron)
- Nacl
Primary outcomes
- Protective effect of L-Arginine on skeletal muscle: V0 and Vmax measurements ACR (Acceptor control ratio)=Vmax/V0 — Immediate post surgery muscle biopsy analysis
Countries
France